Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Journal of Medicinal Chemistry · 22.08.2024 · 67 (16) · 14125-14154
DOI: 10.1021/acs.jmedchem.4c00971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.08.2024. Verfasst von Changwei Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: Transcription Factors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, Oncopia Therapeutics Inc..
Abstract (Originalsprache)
The bromodomain-containing protein BRD9 has emerged as an attractive therapeutic target. In the present study, we successfully identified a number of highly potent BRD9 degraders by using two different cereblon ligands developed in our laboratory. Further optimization led to the discovery of CW-3308 as a potent, selective, and orally bioavailable BRD9 degrader. It displayed degradation potency (DC50) 90% against BRD9 in the G401 rhabdoid tumor and HS-SY-II synovial sarcoma cell lines and had a high degradation selectivity over BRD7 and BRD4 proteins. CW-3308 achieved 91% of oral bioavailability in mice. A single oral dose efficiently reduced the BRD9 protein by >90% in the synovial sarcoma HS-SY-II xenograft tumor tissue. Oral administration effectively inhibited HS-SY-II xenograft tumor growth in mice. CW-3308 is a promising lead compound for further optimization and extensive evaluation for the treatment of synovial sarcoma, rhabdoid tumor, and other BRD9-dependent human diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Medicinal Chemistry, College of Pharmacy,, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Rohan Kalyan Rej, Tianfeng Xu, Jelena Tošović, Duxin Sun, Shaomeng Wang
Förderung
- NCI NIH HHS
- National Cancer Institute
- Oncopia Therapeutics Inc.
- Proteovant Therapeutics Inc.
Zitieren
APA
Wang, C., Wang, M., Wang, Y., Rej, R. K., Aguilar, A., Xu, T., Bai, L., Tošović, J., McEachern, D., Li, Q., Sarkari, F., Wen, B., Sun, D., & Wang, S. (2024). Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. Journal of Medicinal Chemistry, 67(16), 14125-14154. https://doi.org/10.1021/acs.jmedchem.4c00971
Vancouver
Wang C, Wang M, Wang Y, Rej RK, Aguilar A, Xu T, et al. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. Journal of Medicinal Chemistry. 2024;67(16):14125-14154. doi:10.1021/acs.jmedchem.4c00971
BibTeX
@article{Wang2024,
author = {Wang, Changwei and Wang, Mi and Wang, Yu and Rej, Rohan Kalyan and Aguilar, Angelo and Xu, Tianfeng and Bai, Longchuan and Tošović, Jelena and McEachern, Donna and Li, Qiuxia and Sarkari, Farzad and Wen, Bo and Sun, Duxin and Wang, Shaomeng},
title = {Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {16},
pages = {14125--14154},
doi = {10.1021/acs.jmedchem.4c00971}
}
EUVIMED